Octapharma Donates 30.5 Million International Units of Its Medicine Nuwiq to Treat People with Haemophilia in Developing Countries
2017: Octapharma is pleased to announce the completion of a charitable donation of 30.5 million international units of its human cell-line derived recombinant factor VIII product, Nuwiq®, in collaboration with Project SHARE, North Andover, Massachusetts (USA).
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171121005038/en/
Donation in Nepal of human cell-line derived recombinant factor VIII product Nuwiq (Photo: Business Wire)
Up to 75% of the world's estimated 400,000 people with haemophilia have little or no access to treatment that resolves life- and limb-threatening bleeds, and enables surgery and rehabilitation. A humanitarian program, Project SHARE facilitates the donation of blood-clotting factor products for the treatment of people with haemophilia in need of factor replacement therapy in countries where these medicines are scarce or still unavailable.
Over the last nine months, donations of Nuwiq® have been reaching seriously ill people in need in 16 countries: Armenia, Bahamas, Bangladesh, Barbados, Cambodia, Egypt, Ethiopia, Fiji, Kenya, Honduras, Myanmar, Nepal, Nicaragua, Philippines, Romania and Venezuela.
“We are deeply grateful to Octapharma for allowing us the privilege to serve those with haemophilia in developing countries who have limited or no access to treatment. These donations are saving lives,” said Laureen A. Kelley, the founder of Project SHARE.
“Octapharma has been committed to improving the lives of people with Haemophilia A since 1983. We are glad to continue our donation initiatives, providing access to patients with haemophilia in countries with little to no access to therapy,” remarked Olaf Walter, Board Member at Octapharma AG in Lachen, Switzerland.
“The haemophilia factor concentrates are used on patients suffering from serious joint and musculoskeletal complications and life-threatening bleeds,” said Walter Mwanda, Patron of the Kenya Haemophilia Association. “Assistance to one you do not know is great, and to a child is even greater. The Kenyans, mainly children living with haemophilia, thank you very much.”
“We cannot thank Octapharma and Project SHARE enough to for being so kind and generous,” said Suraksha Mani, of the Nepal Haemophilia Society. “We had limited factor stock when we received the Nuwiq® delivery. People in rural areas now have better access to factor concentrate. We believe this donation has already made positive changes in the lives of many people with haemophilia in Nepal. It has been life-saving and is helping to prevent disabilities.”
“This donation of Nuwiq® will help families with haemophilia in Honduras,” said Maria del Carmen of the Honduran Haemophilia Society. “The use of this medicine will serve families because their children and young people will have factor doses in their homes and therefore not miss classes in their schools and universities.”
Antonia Luque, Venezuelan Association for Haemophilia, added “We are currently going through a crisis for which we do not have the medicines that people need. There are currently 2185 people living with haemophilia A in Venezuela. Please accept our gratitude for such a valuable donation that will come to relieve cases of our population who are suffering from haemophilia A.”
About Haemophilia A
Haemophilia A is an X-linked hereditary disorder caused by factor VIII (FVIII) deficiency which, if left untreated, leads to haemorrhages in muscles and joints and consequently to arthropathy and severe morbidity. FVIII replacement prophylactic treatment reduces the number of bleeding episodes and the risk of permanent joint damage. This rare disorder affects one in every 5,000 to 10,000 men worldwide. However, globally, 75% of haemophilia cases are still left undiagnosed or untreated.
About Nuwiq ®
Nuwiq® is a 4th generation rFVIII protein produced in a human cell line without chemical modification or fusion with any other protein. Nuwiq® is naturally suited to individually tailored prophylaxis while addressing immunogenicity in patients with haemophilia A. Nuwiq® is cultured without additives of human or animal origin, is devoid of antigenic non-human protein epitopes and has a high affinity for the von Willebrand coagulation factor. Nuwiq® treatment has been assessed in seven completed clinical trials which included 201 previously treated patients (PTP, 190 individuals) with severe Haemophilia A, including 59 children. Nuwiq® is approved for use in the treatment and prophylaxis of bleeding across all age groups of PTPs with haemophilia A in the EU, US, Canada, Australia, Latin America and Russia. Further worldwide submissions for Nuwiq® are planned.
Disclaimer: All patients treated with coagulation factor VIII products should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests.
About Project SHARE
Project SHARE is a humanitarian program that donates blood-clotting medicine called factor to developing countries. Recipients are patients, doctors, clinics, and hospitals in countries where factor is scarce or unavailable. Project SHARE saves lives.
Project SHARE has donated more than 53 million units—approximately $53 million—of factor to thousands of patients in more than 70 developing countries.
For more information visit www.kelleycom.com/projectshare
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. As a family-owned company, Octapharma believes in investing to make a difference in people’s lives and has been doing so since 1983; because it’s in our blood.
In 2016, the Group achieved €1.6 billion in revenue, an operating income of €383 million and invested €249 million to ensure future prosperity. Octapharma employs more than 7,100 people worldwide to support the treatment of patients in 113 countries with products across three therapeutic areas:
- Haematology (coagulation disorders)
- Immunotherapy (immune disorders)
- Critical care
Octapharma owns six state-of-the-art production facilities in Austria, France, Germany, Mexico and Sweden.
For more information visit www.octapharma.com
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
WELL Building Standard Gaining Momentum in Europe18.5.2018 17:47 | Tiedote
As Greenbuild Europe came to a close in Berlin, the International WELL Building Institute™ (IWBI™) used the occasion to highlight how the WELL Building Standard™ (WELL™) has elevated health and well-being to the forefront of sustainability conversations across Europe. WELL continues to advance the healthy building movement as the premier standard for buildings, interior spaces and communities seeking to implement, validate and measure features that promote human health and wellness. The resonance of the program has spurred innovations across the building, design and construction industries, providing projects with customizable approaches to address geographical and cultural health concerns. To date, WELL has enrolled more than 830 projects encompassing over 155 million square feet of real estate in 32 countries worldwide. In Europe nearly 190 projects across 13 countries are engaged with WELL, representing 25% of global WELL project square footage. The strong growth of WELL over the pa
Utimaco Announces Intent to Acquire Atalla from Micro Focus18.5.2018 12:03 | Tiedote
Utimaco, the global #2 in Hardware Security Modules (HSMs), today announced the intent to acquire the Atalla HSM and ESKM business lines from Micro Focus, which were previously owned by Hewlett Packard Enterprise (HPE) prior to the September 2017 merger of its Software business with Micro Focus. Germany-based Utimaco, active in the HSM market for over 35 years, is a global manufacturer of general purpose HSMs. Utimaco has built its market leading position focusing on indirect sales through OEM or channel business partners and selling its SecurityServer product line into industries as diverse as automotive, government, media & entertainment, smart metering, semiconductors, telecommunications and the banking and financial services sectors. Utimaco is traditionally strong in its German home market based on its longstanding German banking association certification (DK) and has recently achieved PCI accreditation for the SecurityServer product line. With the acquisition of Atalla, one of th
Janssen to Present New Data in Urothelial, Haematologic and Prostate Cancers at ASCO 2018, including Best of ASCO Selections18.5.2018 10:00 | Tiedote
The Janssen Pharmaceutical Companies of Johnson & Johnson, today announced 21 company-sponsored abstracts will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL on June 1-5. New data analyses in support of a portfolio of products, including the investigational treatments erdafitinib and apalutamide, as well as approved treatments Imbruvica® (ibrutinib), Darzalex® (daratumumab), and Zytiga® (abiraterone acetate) will be highlighted across urothelial, haematologic and prostate cancers. Notably, Phase 2 trial results for the investigational compound erdafitinib, which received U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation, will be presented during an oral presentation on Sunday, June 3 (Abstract #4503).1,2 For haematologic cancers, Phase 3 data from the iNNOVATE study will provide the first look at ibrutinib plus rituximab versus placebo plus rituximab in patients with newly diagnosed and relapsed/refractory Wald
Karisma Hotels & Resorts to Open Allure Palazzi Kotor Bay Hotel by Karisma in June 201818.5.2018 09:00 | Tiedote
Karisma Hotels & Resorts, an award-winning luxury hotel collection which owns and manages properties in Latin America, the Caribbean and Europe, is pleased to announce the opening of Allure Palazzi Kotor Bay Hotel by Karisma in June 2018. Built from the ground up in Montenegro’s idyllic Dobrota, the exclusive five-star beachfront property seamlessly blends stunning architecture and design with its mountainous landscape, offering spellbinding views of Kotor Bay. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180517006456/en/ Rendering of Allure Palazzi Kotor Bay (Photo: Business Wire) Sitting on Kotor Bay’s only private beach, the resort features 89 premium guestrooms, 10 villas with private beachfront access, and three breathtaking penthouse suites, each with a balcony or terrace. Allure Palazzi Kotor Bay’s accommodations encompass sumptuous bedding, divine amenities, and carefully selected color palettes bringing the sunny
Siemens Financial Services Selects GTC’s @GlobalTrade Platform for Management of Export Documentary Credits18.5.2018 07:00 | Tiedote
GlobalTrade Corporation (GTC) has announced today that Siemens Financial Services (SFS) has selected its @GlobalTrade Multi-bank Trade Finance Platform for management of its export documentary credits. The platform will be initially rolled out in Germany and thereafter expanded to Siemens entities globally. The system will electronically aggregate all incoming documentary credits in a global database, facilitate review and approval, assist in preparation of compliant documents and enable faster presentation of documents electronically to advising and issuing banks. Gerhard Heubeck, Head of Trade Finance Advisory at Siemens Financial Services, reasons the need for the new system implementation as follows: "After many years of using one of the first standard IT systems available for export documentary credits, the time has come to find a successor tool capable to meet the new requirements such as multi-client capability, processing of new SWIFT message formats, global accessibility, and
PayPal Significantly Expands Global Omnichannel Platform With Acquisition of iZettle18.5.2018 01:35 | Tiedote
PayPal Holdings, Inc. (NASDAQ: PYPL) announced today that it has agreed to acquire iZettle, the leading small business commerce platform in Europe and Latin America, for $2.2 billion USD. The acquisition of iZettle significantly expands PayPal’s in-store presence, strengthening PayPal’s platform to help millions of small businesses around the world grow and thrive in an omnichannel retail environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180517006443/en/ Left to right: Jacob de Geer, CEO and Co-Founder of iZettle, Dan Schulman, President and CEO of PayPal, and Bill Ready, EVP, Chief Operating Officer of PayPal. (Photo: Business Wire) “Small businesses are the engine of the global economy and we are continuing to expand our platform to help them compete and win online, in-store and via mobile,” said PayPal President and CEO Dan Schulman. “iZettle and PayPal are a strategic fit, with a shared mission, values and cult
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme